INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis

Benzinga · 1d ago
  • VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
  • Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe